

Do more than just manage arthritis pain

Adequan Canine offers proven relief and reliable protection to help:¹

RESTORE

joint lubrication

RELIEVE

inflammation

RENEW

the building blocks of healthy cartilage

The specific mechanism of action of Adequan[®] in canine joints is not known.¹



Adequan Canine[®]
polysulfated glycosaminoglycan

Treat the Disease with Adequan Canine

With Adequan[®] Canine (polysulfated glycosaminoglycan), you have a way to proactively treat canine osteoarthritis (OA) and not just manage or control clinical signs of the disease. It's the only FDA-approved drug proven to treat the disease of canine arthritis AND its clinical signs – like pain and inflammation.¹ Adequan Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

Early Treatment Can Make a Difference



Pet owners may not be aware of the subtle changes that could signal their dog is experiencing joint pain. Prescribing Adequan Canine early, when first diagnosed, before cartilage wears away completely, can help improve patient outcomes.




Without treatment, arthritis can cause the deterioration of joint cartilage, and surrounding tissue and fluid; leading to bone-on-bone contact, chronic inflammation, and the loss of mobility.²

Please see Important Safety Information on the reverse side. 

Product Features	Adequan Canine*	Joint Supplements**	NSAIDs	Anti-NGF mAbs	Medical Devices**
Only FDA-approved disease-modifying osteoarthritis drug (DMOAD) for dogs ¹	✓	✗	✗	✗	✗
FDA-reviewed studies with proven efficacy results for treating OA disease process in dogs ¹	✓	✗	✗	✗	✗
Diffuses into the joints and helps rebuild cartilage ¹	✓	✗	✗	✗	✗
Proven to inhibit catabolic enzymes and promote anabolic activity in synovial joints ¹	✓	✗	✗	✗	✗
Proven to reduce inflammation	✓	✗	✓	✓	✗
Veterinary prescription only	✓	✗	✓	✓	?
Adherence to FDA drug label requirements	✓	✗	✓	✓	?
Decades of post-marketing monitoring and a long safety profile	✓	✗	✓	✗	✗
Controls and treats more than just arthritis inflammation and pain to improve pet activity	✓	✗	✗	✗	✗

*The specific mechanism of action of Adequan® in canine joints is not known. **Not FDA-approved. All products have the potential for adverse events that should be considered in overall management of any disease.



Scan here to view the Adequan Canine mode of action video.

For more information:



1-800-458-0163



adequancanine.com



Adequan® Canine polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL

INDICATIONS AND USAGE. Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information at adequancanine.com.

1. Adequan® Canine (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.

2. 2016 NAVC Proceedings, Osteoarthritis in Dogs and Cats: Novel Therapeutic Advances, M Epstein, DVM, DABVP C/F, CVPP; K Kirkby Shaw, DVM, MS, PhD, DACVS, DACVSMR.